Published in Blood Weekly, October 27th, 1997
A goal of the trial was to determine the ability of TP10 to reduce reperfusion injury and improve lung function in patients with end-stage pulmonary disease who were undergoing lung transplant surgery. Evaluations of the safety of TP10 in this indication continue, and are scheduled to conclude before the end of year.
The results showed that at 24 hours after surgery, significantly fewer of the patients receiving TP10...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.